OKYO Pharma
  • Home
  • About
    • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Focus
    • Neuropathic Corneal Pain
    • Rare Corneal Disease
  • Urcosimod
    • Mechanism of Action
    • Preclinical Data
  • NCP Expanded Access
  • Pipeline
    • Overview
    • Urcosimod Development Timeline
    • NEPTUNE Clinical trial
  • Investors
    • Investors
    • Share Information
    • Shareholder Services
    • Investor Presentation
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press releases
    • In The News
  • Contact
  • Linkedin
  • Twitter
Select Page
Investors

Analyst Coverage

NASDAQ: OKYO

    • Share Information
    • Shareholder Services
    • Investor Presentation
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance

 

H.C Wainwright & CO Research Report Phase 3 Start Oct 2026 Reit Buy PT $5

View Report

H.C Wainwright & CO Research Report FDA Update Jan 2026 Reit PT $7

View Report

H.C Wainwright & CO Research Report Update Jan 2026 Reit PT $7

View Report

H.C Wainwright & CO Research Report Update Jan 2026 Reit PT $7

View Report

H.C Wainwright & CO Research Report Update Dec 2025 Reit PT $7

View Report

H.C Wainwright & CO Research Report Sept 2025 Reit PT $7

View Report

H.C Wainwright & CO Research Report Feb 2025 Reit PT $7

View Report

H.C Wainwright & CO Reit BUY RAISE PT TO $6 FEB 2024

View Report

H.C Wainwright & CO Reit BUY PT TO $5

View Report

Lucid Update Jan 2026 Reit Buy PT $13

View Report

Lucid Coverage Initiation July 2025 Buy PT $13

View Report

Piper Sandler Update October 2026 Overweight PT $7

View Report

Piper Sandler Update August 2026 Overweight PT $7

View Report

Piper Sandler Update July 2026 Overweight PT $7

View Report

Piper Sandler HOT COMMENT July 2026 Overweight PT $7

View Report

Piper Sandler Coverage Initiation Overweight PT $7

View Report

B Riley Coverage Initiation BUY PT $5

View Report

Goldman Research Company Update Raise PT $8

View Report

OKYO PHARMA

Explore

  • About
  • Disease Focus
  • Urcosimod
  • Pipeline
  • Investors
  • News
  • Contact

Legal

  • Legal
  • Privacy Policy

Follow

  • Follow
  • Follow

© OKYO Pharma, Limited | 2023